Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription 30.01.2023 1 AIDS 1 Am J Gastroenterol 1 Clin Infect Dis 1 Gut 4 J Hepatol 4 J Viral Hepat 5 PLoS One 2 Transplantation 2 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AIDS

1. SINGH KP, Pallett LJ, Singh H, Chen A, et al
   Pro-fibrogenic role of alarmin HMGB1 in HIV-HBV co-infection.
   AIDS. 2022 Nov 17. pii: 00002030-990000000-00152.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. MARTIN P, Jacobson IM
   New Therapies and Management Options for Hepatitis D.
   Am J Gastroenterol. 2023 Jan 30. doi: 10.14309/ajg.0000000000002153.
   PubMed        
   
   

   
   Clin Infect Dis

3. SOWAH LA, Smeaton L, Brates I, Bhattacharya D, et al
   Perspectives on Adherence from the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach with 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.
   Clin Infect Dis. 2023 Jan 24:ciad034. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Gut

4. JANSSEN HLA, Hou J, Asselah T, Chan HLY, et al
   Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection.
   Gut. 2023 Jan 25:gutjnl-2022-328041. doi: 10.1136/gutjnl-2022-328041.
   PubMed         Abstract available
   
   

   
   J Hepatol

5. LUCIFORA J, Alfaiate D, Pons C, Michelet M, et al
   Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms.
   J Hepatol. 2023 Jan 23:S0168-8278(23)00016-8. doi: 10.1016/j.jhep.2023.
   PubMed         Abstract available
   
   
6. MAALEJ NH, Collins IJ, Ades AE, Scott K, et al
   Modelling the potential effectiveness of hepatitis C screening and treatment strategies during pregnancy in Egypt and Ukraine.
   J Hepatol. 2023 Jan 17:S0168-8278(23)00014-4. doi: 10.1016/j.jhep.2022.
   PubMed         Abstract available
   
   
7. SANDMANN L, Tergast TL, Wedemeyer H, Deterding K, et al
   3P and 5P model of limited value for the detection of clinically significant portal hypertension in patients with hepatitis delta.
   J Hepatol. 2023 Jan 17:S0168-8278(23)00010-7. doi: 10.1016/j.jhep.2023.
   PubMed        
   
   
8. CHALASANI N, Li YJ, Dellinger A, Navarro V, et al
   Clinical features, outcomes, and HLA risk factors associated with nitrofurantoin-induced liver injury.
   J Hepatol. 2023;78:293-300.
   PubMed         Abstract available
   
   

   
   J Viral Hepat

9. FEI Y, Wang Z, Huang M, Wu X, et al
   MiR-155 regulates M2 polarization of hepatitis B virus-infected tumor-associated macrophages which in turn regulates malignant progression of hepatocellular carcinoma.
   J Viral Hepat. 2023 Jan 26. doi: 10.1111/jvh.13809.
   PubMed         Abstract available
   
   
10. WANG J, Huang R, Liu J, Lai R, et al
    A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13808.
    PubMed         Abstract available
    
    
11. TERRAULT NA, Slepin J, Kanner R, Gailloux K, et al
    Strategies to Increase Primary Care Provider Capacity for Hepatitis C Care: The California ECHO-PLUS Study.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13807.
    PubMed         Abstract available
    
    
12. LIAN M, Wang Q, Chen S, Yang Y, et al
    The association of serum immunoglobulin and complement levels and liver fibrosis and inflammation stage in patients with chronic hepatitis B.
    J Viral Hepat. 2023 Jan 25. doi: 10.1111/jvh.13810.
    PubMed         Abstract available
    
    

    
    PLoS One

13. WONG WB, Seetasith A, Hung A, Zullig LL, et al
    Impact of list price changes on out-of-pocket costs and adherence in four high-rebate specialty drugs.
    PLoS One. 2023;18:e0280570.
    PubMed         Abstract available
    
    
14. SY A, McCabe L, Hudson E, Ansari AM, et al
    Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
    PLoS One. 2023;18:e0280551.
    PubMed         Abstract available
    
    
15. AMBAYE E, Ormago MD, Ali MM
    Sero-prevalence and associated factors of sexually transmitted infections among youth-friendly services Attendees.
    PLoS One. 2023;18:e0279900.
    PubMed         Abstract available
    
    
16. DAVITKOV P, Hoffman K, Falck-Ytter Y, Wilson B, et al
    Increasing liver stiffness is associated with higher incidence of hepatocellular carcinoma in hepatitis C infection and non-alcoholic fatty liver disease-A population-based study.
    PLoS One. 2023;18:e0280647.
    PubMed         Abstract available
    
    
17. STEINBRINK JM, Miller C, Myers RA, Sanoff S, et al
    Transcriptional responses define dysregulated immune activation in Hepatitis C (HCV)-naive recipients of HCV-infected donor kidneys.
    PLoS One. 2023;18:e0280602.
    PubMed         Abstract available
    
    

    
    Transplantation

18. CHU HS, Killeen OJ, Hsieh YT, Su TH, et al
    Maximize Donor Cornea Use in a Hepatitis B Endemic Area via Serology Matching.
    Transplantation. 2023 Jan 25. doi: 10.1097/TP.0000000000004460.
    PubMed         Abstract available
    
    
19. HUME SJ, Thompson AJ, Holmes JA
    Editorial on "Maximize Donor Cornea Use in a Hepatitis B Endemic Area via Serology Matching".
    Transplantation. 2023 Jan 25. doi: 10.1097/TP.0000000000004461.
    PubMed        
    
    

    
    Vaccine

20. KIRTLAND KA, Raghunathan T, Patel Murthy B, Li J, et al
    Estimating vaccination coverage for routinely recommended vaccines among children aged 24months and adolescents aged 13 through 17years using data from immunization information systems in the United States.
    Vaccine. 2022 Nov 7. pii: S0264-410X(22)01341.
    PubMed         Abstract available
    
    
21. TRICOU V, Eyre S, Ramjee M, Collini P, et al
    A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country.
    Vaccine. 2023 Jan 19:S0264-410X(23)00007-5. doi: 10.1016/j.vaccine.2023.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: